trending Market Intelligence /marketintelligence/en/news-insights/trending/DicLe7aNv5_vpfRHN7sLNQ2 content esgSubNav
In This List

TherapeuticsMD submits FDA application for hot flash drug

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


TherapeuticsMD submits FDA application for hot flash drug

TherapeuticsMD Inc. submitted a new drug application to the U.S. Food and Drug Administration for TX-001HR to treat moderate-to-severe vasomotor symptoms, or hot flashes and night sweats, due to menopause.

The treatment is a bio-identical hormone therapy combination of estradiol and progesterone in an oral softgel. Vasomotor symptoms arising from menopause include night sweats, hot flashes and flushes.

The submission is supported by positive results from the phase 3 Replenish trial of TX-001HR. TherapeuticsMD expects to hear back from the FDA about 74 days after the application's submission.